Drug Shortage Report for AA-RISEDRONATE DR
| Report ID | 171833 |
| Drug Identification Number | 02493268 |
| Brand name | APO-RISEDRONATE DR |
| Common or Proper name | RISEDRONATE DR |
| Company Name | AA PHARMA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | RISEDRONATE SODIUM |
| Strength(s) | 35MG |
| Dosage form(s) | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Packaging size | 30 BTL |
| ATC code | M05BA |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-10-12 |
| Estimated end date | 2023-01-06 |
| Actual end date | 2023-01-05 |
| Shortage status | Resolved |
| Updated date | 2023-01-06 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1165 CREDITSTONE ROAD VAUGHAN, ONTARIO CANADA L4K 4N7 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2023-01-06 | French | Compare |
| v7 | 2023-01-06 | English | Compare |
| v6 | 2022-12-23 | French | Compare |
| v5 | 2022-12-23 | English | Compare |
| v4 | 2022-12-02 | French | Compare |
| v3 | 2022-12-02 | English | Compare |
| v2 | 2022-10-14 | French | Compare |
| v1 | 2022-10-14 | English | Compare |
Showing 1 to 8 of 8